病原细菌多糖疫苗和多糖结合疫苗研究进展  

Progress on Polysaccharide Vaccines and Glycoconjugate Vaccines of Bacteria

作　　者：潘超[1] 朱力[1] 王恒樑[1] 

机构地区：[1]军事医学科学院生物工程研究所,病原微生物生物安全国家重点实验室,北京100071

出　　处：《生物技术通讯》2013年第5期705-709,共5页Letters in Biotechnology

基　　金：国家自然科学基金(81125012;81171531);国家基础研究发展计划(2011CB504901)

摘　　要：在许多病原细菌中,荚膜多糖和O抗原多糖能够刺激机体产生保护性抗体,因此利用病原细菌的多糖制成的疫苗能有效预防传染病,同时避免了病原细菌耐药性的出现。此类疫苗包括多糖疫苗和多糖结合疫苗。细菌体内糖基化的发现,使得利用生物法生产多糖结合疫苗成了多糖结合疫苗生产的热门方向。我们简要综述了多糖疫苗和多糖结合疫苗在研究和应用方面的主要进展。Capsular polysaccharide and O-antigen polysaccharide of pathogens can stimulate the body to produce protective antibodies. The vaccines made by pathogenic bacterial polysaccharide can effectively address the preven-tion of infectious diseases and avoid the resistance to antibiotics. This kind of vaccines include polysaccharide vac-cines and glycoconjugate vaccines. The discovery of protein glycosylation pathway in bacteria has been evoking the enthusiasm of researchers to develop glycoconjugate vaccines by bio-engineering technology. The research and appli-cation of polysaccharide vaccines and glycoconjugate vaccines were reviewed here.

关 键 词：多糖疫苗 多糖结合疫苗 病原细菌 

分 类 号：R392.1[医药卫生—免疫学]